Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice

被引:25
作者
Serrano, A
Menéndez, J
Casarejos, MJ
Solano, RM
Gallego, E
Sánchez, M
Mena, MA
de Yebenes, JG
机构
[1] Hosp Ramon & Cajal, Dept Invest, Serv Neurobiol, E-28034 Madrid, Spain
[2] Univ Autonoma Madrid, Fdn Jimenez Diaz, Dept Neurol, E-28040 Madrid, Spain
关键词
park-2; gene; calcium antagonist; dopamine neurons; astrocytes; microglia; glutathione; apoptosis; locomotor activity; dyskinesias; Parkinson's disease;
D O I
10.1016/j.neuropharm.2005.03.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cinnarizine, a calcium antagonist that produces parkinsonism in humans, induces behavioural changes such as alopecia, bucolingual dyskinesia and reduction of motor activity in female parkin knock out (PK-KO) mice but not in wild-type (WT) controls. PK-KO mice have high striatal dopamine levels and increased dopamine metabolism in spite of low reduced tyrosine hydroxylase protein. Cinnarizine, which blocks dopamine receptors and increases dopamine release, further increased dopamine metabolism. PK-KO mice increased GSH levels as a compensatory mechanism against enhanced free radical production related to acceleration of dopamine turnover. Neuronal markers, such as P-tubulin slightly increased in PK-KO and furthermore with cinnarizine. Astroglial markers were decreased in PK-KO mice, and this effect was potentiated by cinnarizine, suggesting abnormal glia in these animals. Microglia was hyperactivated in PK-KO midbrain, suggesting inflammation in these animals. Proapoptotic proteins were increased by cinnarizine and, to a lesser extent, in PK-KO mice. Our data indicate that mutation of parkin is a risk factor for drug-induced parkinsonism. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:208 / 219
页数:12
相关论文
共 33 条
[1]   A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe [J].
Abbas, N ;
Lücking, CB ;
Ricard, S ;
Dürr, A ;
Bonifati, V ;
De Michele, G ;
Bouley, S ;
Vaughan, JR ;
Gasser, T ;
Marconi, R ;
Broussolle, E ;
Brefel-Courbon, C ;
Harhangi, BS ;
Oostra, AB ;
Fabrizio, E ;
Böhme, GA ;
Pradier, L ;
Wood, NW ;
Filla, A ;
Meco, G ;
Denefle, P ;
Agid, Y ;
Brice, A .
HUMAN MOLECULAR GENETICS, 1999, 8 (04) :567-574
[2]   EFFECT OF ETHANOL ON HYDROXYLATION OF TYROSINE AND TRYPTOPHAN IN RAT-BRAIN IN-VIVO [J].
CARLSSON, A ;
LINDQVIST, M .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1973, 25 (06) :437-440
[3]   β-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation -: Cross-talk with α-synuclein and implication for Parkinson's disease [J].
da Costa, CA ;
Masliah, E ;
Checler, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (39) :37330-37335
[4]   Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death [J].
Darios, F ;
Corti, O ;
Lücking, CB ;
Hampe, C ;
Muriel, MP ;
Abbas, N ;
Gu, WJ ;
Hirsch, EC ;
Rooney, T ;
Ruberg, M ;
Brice, A .
HUMAN MOLECULAR GENETICS, 2003, 12 (05) :517-526
[5]   PARKINSONISM ASSOCIATED WITH CALCIUM-CHANNEL BLOCKERS - A PROSPECTIVE FOLLOW-UP-STUDY [J].
GARCIARUIZ, PJ ;
DEYEBENES, JG ;
JIMENEZJIMENEZ, FJ ;
VAZQUEZ, A ;
URRA, DG ;
MORALES, B .
CLINICAL NEUROPHARMACOLOGY, 1992, 15 (01) :19-26
[7]   Genes and parkinsonism [J].
Hardy, J ;
Cookson, MR ;
Singleton, A .
LANCET NEUROLOGY, 2003, 2 (04) :221-228
[8]   Molecular findings in familial Parkinson disease in Spain [J].
Hoenicka, J ;
Vidal, L ;
Morales, B ;
Ampuero, I ;
Jiménez-Jiménez, FJ ;
Berciano, J ;
del Ser, T ;
Jiménez, A ;
Ruíz, PG ;
de Yébenes, JG .
ARCHIVES OF NEUROLOGY, 2002, 59 (06) :966-970
[9]   Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse [J].
Itier, JM ;
Ibáñez, P ;
Mena, MA ;
Abbas, N ;
Cohen-Salmon, C ;
Bohme, GA ;
Laville, M ;
Pratt, J ;
Corti, O ;
Pradier, L ;
Ret, G ;
Joubert, C ;
Periquet, M ;
Araujo, F ;
Negroni, J ;
Casarejos, MJ ;
Canals, S ;
Solano, R ;
Serrano, A ;
Gallego, E ;
Sánchez, M ;
Denèfle, P ;
Benavides, J ;
Tremp, G ;
Rooney, TA ;
Brice, A ;
de Yébenes, JG .
HUMAN MOLECULAR GENETICS, 2003, 12 (18) :2277-2291
[10]   Drug-induced movement disorders [J].
JimenezJimenez, FJ ;
GarciaRuiz, PJ ;
Molina, JA .
DRUG SAFETY, 1997, 16 (03) :180-204